Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(0)
# 4351
Out of 5,270 analysts
27
Total ratings
30.43%
Success rate
-9.86%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Mind Medicine | Initiates Coverage On: Outperform | 23 | 6.28 | 266.24% | 1 | Jan 28, 2025 | |
Cabaletta Bio | Downgrades: In-Line | 15 6 | 1.69 | 255.03% | 2 | Dec 20, 2024 | |
argenx | Maintains: Outperform | 675 706 | 630.51 | 11.97% | 4 | Nov 21, 2024 | |
Sarepta Therapeutics | Maintains: Outperform | 179 170 | 101.28 | 67.85% | 9 | Nov 7, 2024 | |
Jasper Therapeutics | Maintains: Outperform | 65 65 | 5.72 | 1036.36% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 20 | 4.3 | 365.12% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 201 206 | 172.49 | 19.43% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 62 66 | 46.58 | 41.69% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 22 | 1.96 | 1022.45% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 10 | 2.42 | 313.22% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 159 165 | 211.25 | -21.89% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 60 | 13.52 | 343.79% | 1 | Oct 5, 2022 |